Nima Sievers
About Nima Sievers
Nima Sievers is a District Business Leader at Alkermes in St. Louis, Missouri, with extensive experience in pharmaceutical sales and management.
Company
Nima Sievers currently works at Alkermes as the District Business Leader in St. Louis, Missouri, United States. Previously, he served as the Senior Territory Business Manager at Alkermes from 2018 to 2021, offering 3 years of dedicated service. His role focuses on managing business operations and sales strategies within the district.
Title
Nima Sievers holds the position of District Business Leader at Alkermes. In his role, he oversees the sales strategies and business operations within his assigned district, employing his extensive experience in the pharmaceutical industry.
Education and Expertise
Nima Sievers studied at St. Louis College of Pharmacy, where he obtained a Bachelor of Science degree in Pharmacy from 1991 to 1996. He also attended Little Rock Central High School, graduating Cum Laude with a High School Diploma from 1989 to 1991. His background in pharmacy enhances his ability to understand and communicate complex medical information effectively.
Background
Nima Sievers has a robust background in the pharmaceutical industry, with diverse roles spanning over two decades. His career journey includes roles at Sunovion Pharmaceuticals, Pfizer, Medtronic, Warner Lambert/Pfizer, and Express Scripts. Notably, he has significant experience working with academic institutions and community-based hospitals, enhancing his expertise in managed care and the optimization of patient care.
Achievements
Nima Sievers has received multiple awards for his sales performance in the pharmaceutical industry. He possesses a proven track record of successful product launches in the biotechnology and injectable markets. Known for his strong clinical skills and business acumen, Sievers regularly mentors new sales representatives, helping them develop their skills and achieve sales targets. His deep understanding of integrated delivery networks (IDNs) and their impact on pharmaceutical sales underscores his strategic approach to market share growth.